Intravitreal (IVT) Injectables - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The intravitreal (IVT) injectables market size is projected to be USD 14.12 billion in 2025, USD 15.09 billion in 2026, and reach USD 21.01 billion by 2031, growing at a CAGR of 6.85% from 2026 to 2031. This report is segmented by Product Type (Anti-VEGF Agents, Corticosteroids, and More), Indication (AMD, Diabetic Retinopathy, Retinal Vein Occlusion, and More), End User (Hospitals, Specialty Ophthalmology Clinics, and More), Distribution Channel (Hospital, Online Pharmacies, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Intravitreal (IVT) Injectables Market Trends and Insights

Rising Prevalence of Retinal Diseases and Diabetes

The Intravitreal (IVT) injectables market is supported by a growing number of people living with diabetes and by the wider identification of retinal complications in routine diabetes care. Diabetic retinopathy affects 1 in 3 people with diabetes. The International Diabetes Federation projected the adult diabetes population to rise from 537 million in 2021 to 783 million by 2045. Growth is concentrated in low- and middle-income countries in South and Southeast Asia, where eye-care capacity is also improving. A U.S. retrospective analysis of 571,545 intravitreal injections across 238 million patient records found that diabetic eye disease represented 26.9% of treated diagnoses, and annual injection volume tripled between 2017 and 2023. Screening programs and wider use of treatment in proliferative disease bring more patients into active care.

Aging Population and Increasing Age-Related Macular Degeneration

The market also benefits from the increasing number of older patients with age-related macular degeneration, or AMD. A Global Burden of Disease analysis reported 8.06 million people with AMD-related vision impairment in 2021 and projected 21.34 million by 2050. The increase reflects demographic change more than any reduction in disease burden from current treatment patterns. The same analysis found that removing tobacco exposure could reduce projected 2050 AMD cases by 9%. Japan provides an early view of demand in aging Asian populations because it has high prevalence among people older than 70 and a developed reimbursement system. These conditions support recurring treatment demand in established retinal-care systems.

High Treatment Cost and Reimbursement Restrictions

Treatment costs limit access in the Intravitreal (IVT) injectables market, especially where coverage is incomplete or patients face substantial out-of-pocket obligations. U.S. wholesale acquisition costs in 2023 ranged from USD 50 to USD 80 per dose for off-label bevacizumab, USD 1,957.50 for aflibercept 2 mg, USD 2,190 for faricimab, and USD 2,625 for aflibercept 8 mg. The Medicare Part B deductible is USD 283 in 2026, and Original Medicare patients face 20% coinsurance. UnitedHealthcare used step-therapy requirements for VEGF inhibitors in its 2025 commercial medical benefit policy. A 2025 survey found that 85% of retina specialists were concerned about patient access during a compounded bevacizumab shortage, and 63.9% expected treatment-plan changes. Such limits can delay initiation and increase reliance on lower-cost treatments.

Other drivers and restraints analyzed in the detailed report include:

• Longer-Acting Delivery Platforms Reducing Injection Burden
• Growth of Biosimilar and Lower-Cost Retinal Therapies
• Treatment Fatigue, Missed Doses, and Patient Dropout

Segment Analysis

Anti-VEGF agents held 87.31% of the intravitreal (IVT) injectables market share in 2025. Their position reflects broad use in AMD, diabetic macular edema, retinal vein occlusion, and diabetic retinopathy. Prescribers also have long experience with anti-VEGF injection protocols. Faricimab was the first bispecific antibody approved for the eye in the United States in January 2022. U.S. injection rates for faricimab increased more than 5-fold from 2022 to 2023, and the product surpassed ranibizumab use within its first 2 years. The pattern indicates that clinicians may change products when longer durability is established.

Corticosteroids are forecast to be the fastest-growing product type at a 7.65% CAGR through 2031. Their use is increasing in uveitis, refractory diabetic macular edema, and cases with an inadequate anti-VEGF response. Antibiotics and antivirals continue to serve smaller roles in endophthalmitis and viral retinitis. Their demand is linked to the number of intravitreal procedures rather than to the incidence of the main retinal diseases. Antifungals remain the smallest category because use is limited to immunocompromised populations. Biosimilar competition is likely to move investment toward extended-interval products and gene therapies across the Intravitreal (IVT) injectables industry.

AMD held 32.24% of the revenue share in 2025. Its scale rests on clinical evidence, established payer support, and a growing older population in North America, Europe, and Japan. Many patients require ongoing anti-VEGF treatment to maintain vision. The age profile of these regions supports continued demand for retinal services across the Intravitreal (IVT) injectables market. Established care pathways also make AMD a durable source of procedure volume. AMD does not have the highest forecast growth rate among the indications.

Diabetic retinopathy is forecast to grow at an 8.22% CAGR from 2026 to 2031. Rising diabetes prevalence increases the pool of patients at risk of retinal damage. Wider use of anti-VEGF therapy in proliferative diabetic retinopathy can replace or defer panretinal photocoagulation in selected patients. Longer-interval options may also help patients who struggle with monthly or every-2-month schedules. EYLEA HD received FDA approval for macular edema following retinal vein occlusion in November 2025. Uveitis, endophthalmitis, and other retinal disorders remain smaller indications with steady treatment needs.

Complete Report Scope:

• By Product Type
  • Anti-VEGF Agents
  • Corticosteroids
  • Antibiotics
  • Antivirals
  • Antifungals
  • Other Product Types
• By Indication
  • Age-Related Macular Degeneration
  • Diabetic Retinopathy
  • Retinal Vein Occlusion
  • Uveitis
  • Endophthalmitis
  • Macular Edema Associated With Other Retinal Disorders
  • Other Indications
• By End User
  • Hospitals
  • Specialty Ophthalmology Clinics
  • Ambulatory Surgical Centers
  • Other End Users
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other Distribution Channels
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 38.61% of the Intravitreal (IVT) injectables market share in 2025. The region has a high concentration of retina specialists, active clinical trials, and broad reimbursement for branded anti-VEGF therapies. Payer pressure still affects treatment choice and payment levels. Biocon confirmed the Canadian launch of Yesafili no later than July 2025. Mexico is attracting interest as private ophthalmology networks extend coverage in major cities.

Europe remains the second-largest geography in the Intravitreal (IVT) injectables market. Germany, the United Kingdom, France, Italy, and Spain have established reimbursement pathways for anti-VEGF treatment. European Commission approvals for Afqlir and Opuviz in November 2024 broadened biosimilar choice. Hospital tenders can alter product use quickly after a new biosimilar enters the formulary. The United Kingdom has used off-label bevacizumab to control costs, and approved lower-cost options may gain further use.

Asia-Pacific is forecast to expand at an 8.65% CAGR from 2026 to 2031 in the Intravitreal (IVT) injectables market. Aging populations, diabetes, and improving ophthalmology infrastructure are supporting regional demand. Santen launched the EYLEA 8 mg prefilled syringe in Japan on May 21, 2025, at JPY 146,286 (USD 970). Novartis received Japanese approval for Beovu in proliferative diabetic retinopathy in November 2025. India has substantial unmet need and an affordability gap, while regulatory pathways for ophthalmic biologics are developing. The Middle East and Africa and South America remain smaller but increasingly relevant as biosimilar pricing supports access.

List of Companies Covered in this Report:

• 4D Molecular Therapeutics, Inc.
• Abbvie
• Alcon
• Alimera Sciences, Inc.
• Amgen
• Astellas Pharma
• Bausch Health
• Bayer
• Biocon
• Chengdu Kanghong Pharmaceutical Group Co., Ltd.
• EyePoint Pharmaceuticals, Inc.
• Roche
• Novartis
• Outlook Therapeutics, Inc.
• Regeneron Pharmaceuticals
• REGENXBIO
• Samsung Bioepis Co., Ltd.
• Santen Pharmaceuticals
• Viatris

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support